Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Pharmaceuticals, Inc. on September 11, 2013. The filing addresses corporate governance changes, specifically the resignation of two directors and the appointment of a new director and committee member.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignations: Luke Evnin and Fred Middleton resigned from the Board of Directors, effective September 30, 2013. The resignations were not due to any disagreement with the Company regarding operations, policies, or practices.
- New Director Appointment: Dennis L. Winger was appointed as a Class I director until the 2015 Annual Meeting of Stockholders. He brings over 30 years of financial executive experience in the life sciences industry.
- Committee Assignments: Mr. Winger was appointed to the Audit Committee. Dr. Mark A. Kronenfeld was appointed to the Compensation Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the absence of disagreements related to the director resignations.
Key Facts for Investor Verification
- Verify the effective date of the resignations (September 30, 2013) and the tenure of the new director (until the 2015 Annual Meeting).
- Confirm the compensation structure for the new director, which is stated as the Company's standard compensation for non-employee directors.
- Review the attached press release (Exhibit 99.1) for additional context on the Board composition changes.
- Note that this filing does not impact the Company's financial statements or operational metrics.